Merck
Search Within

SCC148

应用筛选条件
关键词:'SCC148'
显示 1-17 共 17 条结果 关于 "SCC148" 范围 论文
Zheng Zhu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 28(21), 4820-4831 (2022-08-04)
Immune checkpoint inhibitors (ICI) in general have shown poor efficacy in bladder cancer. The purpose of this project was to determine whether photodynamic therapy (PDT) with bladder cancer-specific porphyrin-based PLZ4-nanoparticles (PNP) potentiated ICI. SV40 T/Ras double-transgenic mice bearing spontaneous bladder
Vanessa Bellat et al.
Cancer research, 82(7), 1409-1422 (2022-01-19)
The standard treatment of nonmuscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intravesical therapy (IT), which comprises a direct instillation of a solution of Bacillus Calmette-Guérin vaccine or chemotherapy into the bladder. However, the recurrence
Houhong Zhou et al.
Frontiers in pharmacology, 13, 1050774-1050774 (2022-11-18)
A large proportion of bladder cancer (BLCA) patients suffer from malignant progression to life-threatening muscle-invasive bladder cancer (MIBC). Inflammation is a critical event in cancer development, but little is known about the role of inflammation in BLCA. In this study
Dominik Gulyás et al.
PloS one, 17(7), e0270802-e0270802 (2022-07-09)
The basis of the antitumor immunotherapy, of which the purpose is the stimulation of the immune system. We have used two of the Pathogen Associated Molecular Patterns: unmethylated CpG oligonucleotide, a ligand of Toll-like receptor 9 (TLR9), and lipopolysaccharide (LPS)
E C Lattime et al.
Cancer research, 52(15), 4286-4290 (1992-08-01)
Intravesical administration of Bacillus Calmette-Guérin (BCG) is the most effective therapy for superficial transitional cell carcinoma of the bladder although its mechanism of action is not known. To determine if bladder tumors are capable of antigen presentation and thus might
Mathieu Rouanne et al.
The Journal of clinical investigation, 132(12) (2022-05-04)
Patients with high-risk, nonmuscle-invasive bladder cancer (NMIBC) frequently relapse after standard intravesical bacillus Calmette-Guérin (BCG) therapy and may have a dismal outcome. The mechanisms of resistance to such immunotherapy remain poorly understood. Here, using cancer cell lines, freshly resected human
Guangchuan Wang et al.
Cancer discovery, 10(12), 1912-1933 (2020-09-06)
Immune checkpoint blockade (ICB) has shown remarkable clinical efficacy in several cancer types. However, only a fraction of patients will respond to ICB. Here, we performed pooled mutagenic screening with CRISPR-mediated genetically engineered mouse models (CRISPR-GEMM) in ICB settings, and
Andreja Erman et al.
International journal of molecular sciences, 22(12) (2021-07-03)
Non-muscle-invasive bladder cancer is the most common form of bladder cancer. The main problem in managing bladder tumors is the high recurrence after the transurethral resection of bladder tumors (TURBT). Our study aimed to examine the fate of intravesically applied
I C Summerhayes et al.
Journal of the National Cancer Institute, 62(4), 1017-1023 (1979-04-01)
Neoplastic transformation of C57BL/lcrf-a' mouse bladder epithelium was induced in long-term primary cultures by a single 24-hour treatment with 7,12-dimethylbenz[a]anthracene on day 2 of culture. Transformed foci appeared earlier (40--60 days) and at a higher frequency (28%) in cultures from
Lei Zhang et al.
Cancer research, 83(11), 1834-1850 (2023-03-21)
N6-Methyladenosine (m6A) is the most prevalent internal modification of mammalian mRNAs. Recent studies have shown that m6A methyltransferases METTL3 and METTL14 play important roles in urothelial bladder carcinoma (BLCA). To provide a more comprehensive understanding of the m6A regulatory landscape
Pietro Strobbia et al.
Theranostics, 11(9), 4090-4102 (2021-03-24)
For the majority of cancer patients, surgery is the primary method of treatment. In these cases, accurately removing the entire tumor without harming surrounding tissue is critical; however, due to the lack of intraoperative imaging techniques, surgeons rely on visual
Shai White-Gilbertson et al.
Bladder (San Francisco, Calif.), 3(1) (2016-03-22)
The MB49 syngeneic, murine model of bladder cancer has been widely used for more than 35 years. In humans, bladder cancer is one third as prevalent in women as in men, with a trend toward lower prevalence in parous compared
Adnan Deronic et al.
Cancer immunology, immunotherapy : CII, 70(12), 3629-3642 (2021-05-06)
Non-responders to checkpoint inhibitors generally have low tumor T cell infiltration and could benefit from immunotherapy that activates dendritic cells, with priming of tumor-reactive T cells as a result. Such therapies may be augmented by providing tumor antigen in the
Yuexia Liang et al.
Theranostics, 12(18), 7729-7744 (2022-12-02)
Rationale: IgA can induce activation of neutrophils which are the most abundant cell type in blood, but the development of IgA as therapeutic has been confounded by its short half-life and a weak ability to recruit NK cells as effector
Victoria T Fabris et al.
Cancer genetics, 205(4), 168-176 (2012-05-09)
Bladder cancer is frequently associated with chromosomal abnormalities, and the complexity of karyotypes increases with tumor progression. The murine model MB49 is one of the most widely studied models of bladder cancer. We developed the invasive cell line MB49-I by
Sydney X Lu et al.
Cell, 184(15), 4032-4047 (2021-06-26)
Although mutations in DNA are the best-studied source of neoantigens that determine response to immune checkpoint blockade, alterations in RNA splicing within cancer cells could similarly result in neoepitope production. However, the endogenous antigenicity and clinical potential of such splicing-derived
Valentin Baloche et al.
Scientific reports, 11(1), 5227-5227 (2021-03-06)
Mechanisms of tumor immune escape are quite diverse and require specific approaches for their exploration in syngeneic tumor models. In several human malignancies, galectin-9 (gal-9) is suspected to contribute to the immune escape. However, in contrast with what has been
1/1